Sun Pharma Announces Launch of Generic Exelon(R) in US

Sun Pharma Announces Launch of Generic Exelon(R) in US
Company Has 180-Day Marketing Exclusivity 

MUMBAI, India, Jul 01, 2010 (BUSINESS WIRE) -- Sun Pharma announced launch of generic Exelon(R), rivastigmine tartrate capsules for the US market. Earlier, USFDA had granted final approval for the Company's ANDA to market these products.

These generic rivastigmine capsules are therapeutically equivalent of Novartis Exelon(R) Capsules and include four strengths: 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). These strengths of Exelon(R) have annual sales of approximately USD 130 million in the US.

Sun Pharma, being one of the first-to-file an ANDA for generic Exelon(R) with a para IV certification, shares a 180-day marketing exclusivity.

Rivastigmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia associated with Parkinson's disease.

Exelon (R) is a registered trademark of Novartis.

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The Company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

SOURCE: Sun Pharmaceutical Industries Ltd.


Sun Pharma
Uday Baldota
Tel: +91 22 6645 5645, Xtn 605
Tel Direct: +91 22 6645 5605
Mobile: +91 98670 10529
E mail: [email protected]
or
Mira Desai
Tel: +91 22 6645 5645, Xtn 606
Tel Direct: +91 22 6645 5606
Mobile: +91 98219 23797
E mail: [email protected]

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.